Japan has long been regarded as a pharma market with unique challenges where the local knowledge of a domestic partner is essential.
Generally speaking, multinational pharma companies and their western executives will have been more comfortable negotiating the North American and European markets.
But there are real signs that Japan is now making a concerted effort to make its healthcare sector a more open and attractive place to invest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze